ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Intra-Articular Mesenchymal Stromal Cell Injections Are No Different From Placebo in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Dai, Wenli; Leng, Xi; Wang, Jian; Shi, Zhanjun; Cheng, Jin; Hu, Xiaoqing*; Ao, Yingfang*广州中医药大学; 北京大学; 南方医科大学; 1
Arthroscopy - Journal of Arthroscopic and Related Surgery2021-1DOI: 10.1016/j.arthro.2020.10.016
26被引8阅读
引用收藏
分享

摘要

Purpose: To evaluate the efficacy and safety of intra-articular mesenchymal stromal cells (MSCs) injections for knee oste-oarthritis (OA) treatment. Methods: We performed a systematic literature search in PubMed, Embase, Scopus, and the Cochrane Library through April 2020 to identify level I randomized controlled trials (RCTs) that evaluated the clinical efficacy of MSCs versus control treatments for knee OA. Outcomes were analyzed on an intention-to-treat basis with random-effects models. Results: A total of 13 RCTs were included in the meta-analysis. Compared with placebo, there was no significant difference in VAS for pain (mean difference [MD] 1.62, 95% confidence interval [CI -0.60 to 3.85), WOMAC pain score (MD 1.88, 95% CI -0.21 to 3.98), WOMAC function score (MD -0.67, 95% CI -6.54 to 5.19), or WOMAC stiffness score (MD 0.64, 95% CI -0.86 to 2.14) for MSCs. Moreover, the smallest treatment effect of VAS for pain, WOMAC pain score, WOMAC function score, and WOMAC stiffness score did not exceed the minimum clinically important difference (MCID). Additionally, there was no significant difference in percentage of patients crossing the MCID threshold between MSC and placebo groups for VAS for pain (relative risk [RR] 0.93, 95% CI 0.55 to 1.57) or WOMAC total score (RR 0.40, 95% CI 0.13 to 1.21). Compared with hyaluronic acid (HA), MSC injection was associated with significantly better improvement in VAS for pain (MD 2.00, 95% CI 0.94 to 3.07), WOMAC pain score (MD 4.58, 95% CI 0.49 to 8.67), WOMAC total score (MD 14.86, 95% CI 10.59 to 19.13), and WOMAC stiffness score (MD 1.85, 95% CI 0.02 to 3.69). However, the smallest treatment effect of VAS for pain, WOMAC pain score, WOMAC function score, and WOMAC stiffness score did not exceed the MCID. Moreover, there was no significant difference in percentage of patients crossing the MCID threshold between MSC and HA groups for WOMAC total score (RR 0.57, 95% CI 0.21 to 1.55). We also found that MSCs did not increase adverse events compared with HA and placebo. Conclusions: Intra-articular MSC injection was not found to be superior to placebo in pain relief and functional improvement for patients with symptomatic knee OA. However, additional direct testing and combination trials of different type of cells, doses, and number of injections of MSCs are required to further enhance clinical decision making for people with symptomatic knee OA. Level of Evidence: I, meta-analysis of level I studies.

学科与关键词

关键词
PLATELET-RICH PLASMACLINICALLY IMPORTANT IMPROVEMENTSTEM-CELLSHYALURONIC-ACIDHIPCARTILAGEPROGRESSIONMANAGEMENTTHERAPYSTATE
相关
加载中…
  • Combination of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) in the treatment of knee osteoarthritis: a meta-analysis of randomised controlled trials
    Zhao, Jinlong; Liang, Guihong; Han, Yanhong; Yang, Weiyi; Xu, Nanjun; Luo, Minghui; Pan, Jianke; Liu, Jun*; Zeng, Ling-Feng*BMJ Open, 2022, 12(11): e061008.被引 4
  • Author Reply To "Regarding 'Intra-articular Mesenchymal Stromal Cell Injections Are No Different From Placebo in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials'"
    Dai, Wenli*; Leng, Xi; Wang, Jian; Shi, Zhanjun; Cheng, Jin; Hu, Xiaoqing; Ao, YingfangArthroscopy - Journal of Arthroscopic and Related Surgery, 2021, 37(5): 1362-1364.
  • What is the optimal dose of adipose-derived mesenchymal stem cells treatment for knee osteoarthritis? A conventional and network meta-analysis of randomized controlled trials
    Huang, Zongyuan*; Zhang, Shuai; Cao, Mingde; Lin, Zhujian; Kong, Ling; Wu, Xin; Guo, Qianshi; Ouyang, Yuxiang; Song, Yancheng*Stem Cell Research & Therapy, 2023, 14(1): 245.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Arthroscopy - Journal of Arthroscopic and Related Surgery
发表日期
2021-01
卷期
第 37 卷, 第 1 期
页码
340-358
DOI
10.1016/j.arthro.2020.10.016
语言
ENGLISH
期刊收录
NSL
期刊等级
1区
成果收录
SCIE

作者

  • D

    Dai, Wenli (第一作者)

    peking univ

  • L

    Leng, Xi

    1 · guangzhou univ chinese med

查看全部 7 位作者收起作者
  • W

    Wang, Jian

    southern med univ

  • S

    Shi, Zhanjun

    southern med univ

  • C

    Cheng, Jin

    peking univ

  • H

    Hu, Xiaoqing (通讯)

    peking univ

  • A

    Ao, Yingfang (通讯)

    peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417